Igm Biosciences, Inc.

Amgen Fremont Inc.

Trellis Bioscience, Inc.

Medimmune Limited

Trellis Rsv Holdings, Inc.

Igm Biosciences A/s

Dendreon Corporation

Bipar Sciences, Inc.

Bruce Alan Keyt

Orit Foord

Ramesh Baliga

Larry L Green

Leonard G Presta

Ian Nevin Foltz

Chadwick Terence King

Jaspal Singh Kang

Xiao-Chi Jia

Jean M Gudas

Xiao Feng

Qiaojuan Jane Su

Scott L Klakamp

Palaniswami Rathanaswami

Xiao Dong Yang

Ying Liu

Richard F Weber

Robert Raya

Jose Corvalan

Fen Zhang

Lawrence M Kauvar

Ellen J Collarini

Xiao-Dong Yang

Stephen Fitzhugh Carroll

David Charles Blakey

Stephen Charles Emery

Gizette Sperinde

Qing Zhou

Dean Ng

Hung Nguyen

Beatrice Tien-Yi Wang

Max Allen Schwarzer

Marjan Fatholahi

Dan T Stinchcomb

Ole Olsen

Jose R F Corvalan

Edwin L Madison

John P Burnier

Francine Zhifen Chen

Giorgio Senaldi

Valeria S Ossovskaya

Kathy Manchulenko

Gadi Gazit-Bornstein

Marcia M Bieber

Neelima M Bhat

Barry M Sherman

Omar Duramad

Jennifer Hope Richardson

Nelson N H Teng

Max Totrov

Stanislaw K Morkowski

Gerardo Zapata

Beatrice Wang

Caroline Darne Scatena

Rency Yoshimura

Peter Koon Bong Ling

Jerome Moore

Wayne R Godfrey

Jennifer H Richardson

Stephen Charles Astrazeneca R & D Alderley Emery

David C Astrazeneca R & D Alderley Blakey

Nelson NH Teng

Neelirna M Bhat

Xiao Chi Jia

Palani Rathanaswami

Fan Zhang

Peter Koon Ling

Leonard George Presta

The present invention provides binding molecules that include an IgM, IgA, IgG/IgM or IgG/IgA antibody with a modified J-chain that includes a binding moiety that antagonizes a T-cell inhibitory signaling pathway, and their uses.

Binding molecules with modified J-chain

This disclosure provides dimeric, pentameric, and hexameric Tumor Necrosis Factor (TNF) superfamily receptor protein binding molecules and methods of using such binding molecules to direct apoptosis-mediated killing of TNF receptor-expressing cells.

Polynucleotides encoding death domain-containing receptor-5 (DR5) binding molecules

The present invention concerns modified recombinant J-chain polypeptides, binding molecules, such as antibodies comprising the same, and their uses.

Modified J-chain

The present invention concerns binding molecules that comprise an IgM, IgA, IgG/IgM or IgG/IgA antibody with a J-chain modified to include an ADME-modulating moiety, and their uses.

This disclosure provides a multimeric hepatitis B virus (HBV) protein binding molecule, e.g., a dimeric IgA or a pentameric or hexameric IgM binding molecule, comprising at least two bivalent binding units, or variants or fragments thereof, each comprising at least two antibody heavy chain constant regions or fragments thereof, wherein each heavy chain constant region or fragment thereof is associated with an HBV antigen binding domain. The disclosure also provides compositions comprising the multimeric binding molecules, polynucleotides encoding the multimeric binding molecules, and methods to make and use the multimeric binding molecules.

Multi-valent hepatitis B virus antigen binding molecules and uses thereof

The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.

Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof

This disclosure provides a multimeric human immunodeficiency virus (HIV) protein binding molecule, e.g., an dimeric IgA or a pentameric or hexameric IgM binding molecule, comprising at least two bivalent binding units, or variants or fragments thereof, each comprising at least two antibody heavy chain constant regions or fragments thereof, wherein each heavy chain constant region or fragment thereof is associated with an HIV antigen binding domain. Also provided are compositions comprising the multimeric binding molecules, polynucleotides encoding the multimeric binding molecules, and methods to make and use the multimeric binding molecules.

Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof

Aspects of the invention include isolated anti-PD-L1 antibodies, as well as compositions containing such antibodies, and methods of using the same in the treatment of diseases or conditions that are mediated by PD-L1 signaling.

Anti-PD-L1 antibodies

This disclosure provides an IgM antibody or IgM-like antibody comprising a variant J-chain and/or variant IgM heavy chain constant regions that can confer increased serum half-life upon the antibody.

IgM Fc and J-chain mutations that affect IgM serum half-life

The present invention concerns IgA multi-specific binding molecules. In particular, the invention concerns multi-specific, including bispecific, binding molecules comprising IgA heavy chain sequences, and methods for their preparation and use.

IgA multi-specific binding molecules

This disclosure provides pentameric and hexameric CD20 binding molecules and methods of using such molecules to direct complement-mediated, T-cell-mediated, or both complement-mediated and T-cell-mediated killing of CD20-expressing cells.

Multimeric bispecific binding molecules specific for CD20 and CD3

Multimeric death domain-containing receptor-5 (DR5) antibodies and uses thereof

The present invention concerns binding molecules that comprise an IgM, IgA, IgG/IgM or IgG/IgA antibody with a J-chain modified to include an AD-ME-modulating moiety, and their uses.

Growing community of inventors

Hillsborough, CA, United States of America

Bruce Alan Keyt